Literature DB >> 16143567

Anti-CD3 priming generates heterogeneous antigen-specific memory CD4 T cells.

Deepa S Patke1, Mojgan Ahmadzadeh, Adam W Bingaman, Donna L Farber.   

Abstract

Anti-CD3 activation of peripheral T cells is used in adoptive immunotherapy for cancer and HIV infection, but the long-term fate of anti-CD3-primed T cells in vivo is not known. In this study, we demonstrate that anti-CD3-mediated activation of influenza hemagglutinin (HA)-specific TCR-transgenic CD4 T cells results in generation of a long-lived HA-specific memory CD4 T cell population when transferred into lymphocyte-deficient and intact mouse hosts. This anti-CD3-primed memory population is indistinguishable from HA peptide-primed memory CD4 T cells in terms of phenotype, rapid recall function, and enhanced proliferative capacity. Moreover, anti-CD3 priming generates phenotypically heterogeneous memory subsets in lymphoid and non-lymphoid sites. Our results suggest that anti-CD3 has potential efficacy in generating memory responses in adoptive immunotherapies and vaccines and that the tissue distribution and maintenance of heterogeneous lymphoid and non-lymphoid memory T cell subsets are a stochastic process that can occur independent of antigen or TCR specificity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16143567     DOI: 10.1016/j.clim.2005.07.012

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  2 in total

1.  Induction of diverse T cell memory through antibody-mediated activation in mice.

Authors:  Matthew D Taylor; Mariana R Brewer; Clifford S Deutschman
Journal:  Eur J Immunol       Date:  2020-07-29       Impact factor: 5.532

2.  Memory CD4 T cells direct protective responses to influenza virus in the lungs through helper-independent mechanisms.

Authors:  John R Teijaro; David Verhoeven; Carly A Page; Damian Turner; Donna L Farber
Journal:  J Virol       Date:  2010-06-30       Impact factor: 5.103

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.